Evidence map›Paper›PMID 42266746›Full record

ArticleAmerican journal of cancer research2026

BANF1 knockdown impedes thyroid cancer development and boosts CD8

Chuanbing Liu, Zhen Jia, Dan Wei, Huanjun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chuanbing LiuDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology Jinan, Shandong, China.
Zhen JiaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology Jinan, Shandong, China.
Dan WeiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology Jinan, Shandong, China.
Huanjun WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Barrier to Autointegration Factor 1 (BANF1) is a highly evolutionarily conserved small DNA-binding protein, and its dysregulation has been implicated in the development of various diseases. This study seeks to elucidate the role of BANF1 in thyroid cancer and its relevance to tumor immunity. BANF1 expression levels were assessed using Western blot and RT-qPCR. The effects of BANF1 on thyroid cancer cell progression were evaluated using colony formation assays, EdU, Transwell migration/invasion assays, and Flow cytometry (FCM). The effects of BANF1 knockdown on CD8

Indexed as

BANF1CD8+ T cellsexpressionmalignant progressionthyroid cancer

Identifiers

PMID42266746
PMCPMC13243680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.